Compare HWBK & ORGO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HWBK | ORGO |
|---|---|---|
| Founded | 1865 | 1985 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 253.0M | 299.8M |
| IPO Year | 1996 | 2016 |
| Metric | HWBK | ORGO |
|---|---|---|
| Price | $39.43 | $2.36 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $8.50 |
| AVG Volume (30 Days) | 12.6K | ★ 709.8K |
| Earning Date | 04-29-2026 | 05-07-2026 |
| Dividend Yield | ★ 2.49% | N/A |
| EPS Growth | 31.42 | ★ 1600.00 |
| EPS | ★ 0.83 | N/A |
| Revenue | N/A | ★ $564,169,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $26.27 |
| P/E Ratio | $48.18 | ★ N/A |
| Revenue Growth | N/A | ★ 17.04 |
| 52 Week Low | $28.10 | $2.04 |
| 52 Week High | $40.36 | $7.08 |
| Indicator | HWBK | ORGO |
|---|---|---|
| Relative Strength Index (RSI) | 55.17 | 43.20 |
| Support Level | $33.50 | $2.26 |
| Resistance Level | N/A | $2.58 |
| Average True Range (ATR) | 1.56 | 0.11 |
| MACD | 0.06 | 0.00 |
| Stochastic Oscillator | 68.61 | 18.75 |
Hawthorn Bancshares Inc is a financial holding company that, along with its subsidiary bank, provides commercial banking for small and mid sized businesses, including equipment, operating, commercial real estate and SBA loans, and personal banking services such as real estate mortgage lending, installment and consumer loans, certificates of deposit, and checking, savings and money market accounts. It has two segments, banking and wealth management, with the banking segment earning the majority of its revenue and conducting general banking business, offering checking and savings accounts, internet banking, debit cards, certificates of deposit, brokerage services and others. Its primary source of revenue is net interest income derived from lending and deposit taking activities.
Organogenesis Holdings Inc is a regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the advanced wound care, surgical, and sports medicine markets. The company's portfolio of regenerative medicine products in the advanced wound care category includes Apligraf, Dermagraft, PuraPly AM, CYGNUS Dual, etc., and the sports medicine products include NuShield as a surgical barrier and PuraForce as a reinforcement matrix in targeted soft tissue repairs; and Affinity, Novachor, PuraPly MZ, PuraPly AM, and PuraPly SX for management of open wounds in the surgical setting. The company operates in a single segment, that is, regenerative medicine.